Literature DB >> 27543943

Tumor cells with neuronal intermediate progenitor features define a subgroup of 1p/19q co-deleted anaplastic gliomas.

Franck Bielle1,2, François Ducray3,4,5, Karima Mokhtari1,2,6, Caroline Dehais7, Homa Adle-Biassette8, Catherine Carpentier2, Anaïs Chanut1, Marc Polivka8, Sylvie Poggioli2, Shai Rosenberg2, Marine Giry2, Yannick Marie2,6, Charles Duyckaerts1,2, Marc Sanson2,7, Dominique Figarella-Branger9,10, Ahmed Idbaih2,7.   

Abstract

The integrated diagnosis of anaplastic oligodendroglioma, IDH mutant and 1p/19q co-deleted, grade III (O3id ) is a histomolecular entity that WHO 2016 classification distinguished from other diffuse gliomas by specific molecular alterations. In contrast, its cell portrait is less well known. The present study is focused on intertumor and intratumor, cell lineage-oriented, heterogeneity in O3id . Based on pathological, transcriptomic and immunophenotypic studies, a novel subgroup of newly diagnosed O3id overexpressing neuronal intermediate progenitor (NIP) genes was identified. This NIP overexpression pattern in O3id is associated with: (i) morphological and immunohistochemical similarities with embryonic subventricular zone, (ii) proliferating tumor cell subpopulation with NIP features including expression of INSM1 and no expression of SOX9, (iii) mutations in critical genes involved in NIP biology and, (iv) increased tumor necrosis. Interestingly, NIP tumor cell subpopulation increases in O3id recurrence compared with paired newly diagnosed tumors. Our results, validated in an independent cohort, emphasize intertumor and intratumor heterogeneity in O3id and identified a tumor cell subpopulation exhibiting NIP characteristics that is potentially critical in oncogenesis of O3id . A better understanding of spatial and temporal intratumor cell heterogeneity in O3id will open new therapeutic avenues overcoming resistance to current antitumor treatments.
© 2016 International Society of Neuropathology.

Entities:  

Keywords:  1p/19q co-deletion; anaplastic oligodendroglioma; embryonic subventricular zone; neuronal intermediate progenitor

Mesh:

Substances:

Year:  2016        PMID: 27543943     DOI: 10.1111/bpa.12434

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  5 in total

1.  Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions.

Authors:  Anna Luisa Di Stefano; Alberto Picca; Edouard Saragoussi; Franck Bielle; Francois Ducray; Chiara Villa; Marica Eoli; Rosina Paterra; Luisa Bellu; Bertrand Mathon; Laurent Capelle; Véronique Bourg; Arnaud Gloaguen; Cathy Philippe; Vincent Frouin; Yohann Schmitt; Julie Lerond; Julie Leclerc; Anna Lasorella; Antonio Iavarone; Karima Mokhtari; Julien Savatovsky; Agusti Alentorn; Marc Sanson
Journal:  Neuro Oncol       Date:  2020-11-26       Impact factor: 12.300

2.  INSM1 Expression Is Frequent in Primary Central Nervous System Neoplasms but Not in the Adult Brain Parenchyma.

Authors:  Heather M Ames; Lisa M Rooper; John J Laterra; Charles G Eberhart; Fausto J Rodriguez
Journal:  J Neuropathol Exp Neurol       Date:  2018-05-01       Impact factor: 3.685

3.  Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome.

Authors:  Romain Appay; Emeline Tabouret; Mehdi Touat; Catherine Carpentier; Carole Colin; François Ducray; Ahmed Idbaih; Karima Mokhtari; Emmanuelle Uro-Coste; Caroline Dehais; Dominique Figarella-Branger
Journal:  Acta Neuropathol Commun       Date:  2018-09-07       Impact factor: 7.801

4.  CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design.

Authors:  Kurt A Jaeckle; Karla V Ballman; Martin van den Bent; Caterina Giannini; Evanthia Galanis; Paul D Brown; Robert B Jenkins; J Gregory Cairncross; Wolfgang Wick; Michael Weller; Kenneth D Aldape; Jesse G Dixon; S Keith Anderson; Jane H Cerhan; Jeffrey S Wefel; Martin Klein; Stuart A Grossman; David Schiff; Jeffrey J Raizer; Frederick Dhermain; Donald G Nordstrom; Patrick J Flynn; Michael A Vogelbaum
Journal:  Neuro Oncol       Date:  2021-03-25       Impact factor: 12.300

5.  IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.

Authors:  Ryohei Otani; Takeo Uzuka; Fumi Higuchi; Hadzki Matsuda; Masashi Nomura; Shota Tanaka; Akitake Mukasa; Koichi Ichimura; Phyo Kim; Keisuke Ueki
Journal:  Cancer Sci       Date:  2018-06-15       Impact factor: 6.716

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.